Monoclonal antibody: Difference between revisions
Jump to navigation
Jump to search
imported>Howard C. Berkowitz (New page: A '''monoclonal antibody''' is an immune substance "produced by clones of cells such as those isolated after hybridization of activated B-lymphocytes with neop...) |
mNo edit summary |
||
| (3 intermediate revisions by 2 users not shown) | |||
| Line 1: | Line 1: | ||
{{subpages}} | |||
A '''monoclonal antibody''' is an immune substance "produced by clones of cells such as those isolated after hybridization of activated [[Lymphocyte#B-lymphocyte|B-lymphocyte]]s with neoplastic cells. These hybrids are often referred to as [[hybridomas]]." <ref>{{MeSH|Antibody, monoclonal}}</ref> Monoclonal antibodies have extensive applications in clinical medicine and immunochemistry. | A '''monoclonal antibody''' is an immune substance "produced by clones of cells such as those isolated after hybridization of activated [[Lymphocyte#B-lymphocyte|B-lymphocyte]]s with neoplastic cells. These hybrids are often referred to as [[hybridomas]]." <ref>{{MeSH|Antibody, monoclonal}}</ref> Monoclonal antibodies have extensive applications in clinical medicine and immunochemistry. | ||
The [[World Health Organization]] is refining naming conventions for monoclonal antibodies. <ref name=WHOname>{{citation | The [[World Health Organization]] is refining naming conventions for monoclonal antibodies. <ref name=WHOname>{{citation | ||
| url = http://www.who.int/entity/medicines/publications/druginformation/issues/WHO-DI-22-2.pdf | | url = http://www.who.int/entity/medicines/publications/druginformation/issues/WHO-DI-22-2.pdf | ||
| journal = WHO Drug Information | | journal = WHO Drug Information | volume= 22 | issue = 2 | year = 2008 | title = International Nonproprietary Names for monoclonal antibodies: IFPMA proposal | author = Anna-Maija Autere, Nicole Wagner and Georg-Burkhard Kresse | ||
| volume= 22 | |||
| issue = 2 | |||
| year = 2008 | |||
| title = International Nonproprietary Names for monoclonal antibodies: IFPMA proposal | |||
| author = Anna-Maija Autere, Nicole Wagner and Georg-Burkhard Kresse | |||
from Roche on behalf of International Federation of Pharmaceutical Manufacturers & Associations (IFPMA) Biotech Working Group | from Roche on behalf of International Federation of Pharmaceutical Manufacturers & Associations (IFPMA) Biotech Working Group | ||
}}, pp. 97-107</ref> Its original system came from the International Federation of Pharmaceutical Manufacturers & Associations (IFPMA) Biotech Working Group.<ref name=IFPMA>{{citation | }}, pp. 97-107</ref> Its original system came from the International Federation of Pharmaceutical Manufacturers & Associations (IFPMA) Biotech Working Group.<ref name=IFPMA>{{citation | author = International Federation of Pharmaceutical Manufacturers & Associations (IFPMA) Biotech Working Group | title = Proposal to the WHO INN Expert Group: Principles for naming of new monoclonal | ||
| author = International Federation of Pharmaceutical Manufacturers & Associations (IFPMA) Biotech Working Group | antibodies | year = 2008 | url = http://www.ifpma.org/fileadmin/templates/ifpmaissues/pdfs/2008_03_21_IFPMA_Proposal_for_naming_of_new_monoclonals.pdf}}</ref> | ||
| title = Proposal to the WHO INN Expert Group: Principles for naming of new monoclonal | |||
antibodies | Naming of monoclonal antibodies is governed by [[World Health Organization]]’s [http://www.who.int/medicines/services/inn/en/ International Nonproprietary Name] (INN): | ||
| year = 2008 | * [[Human monoclonal antibody]]. INN names end in -umab. Example is [[olaratumab]]. | ||
| url = http://www.ifpma.org/fileadmin/templates/ifpmaissues/pdfs/2008_03_21_IFPMA_Proposal_for_naming_of_new_monoclonals.pdf}}</ref> | * [[Humanized monoclonal antibody]]. INN names end in -zumab. Example is [[benralizumab]]. | ||
* [[Chimeric monoclonal antibody]]. INN names end in -ximab. Example is [[rituximab]]. | |||
==References== | ==References== | ||
{{reflist|2}} | {{reflist|2}}[[Category:Suggestion Bot Tag]] | ||
Latest revision as of 06:00, 21 September 2024
A monoclonal antibody is an immune substance "produced by clones of cells such as those isolated after hybridization of activated B-lymphocytes with neoplastic cells. These hybrids are often referred to as hybridomas." [1] Monoclonal antibodies have extensive applications in clinical medicine and immunochemistry.
The World Health Organization is refining naming conventions for monoclonal antibodies. [2] Its original system came from the International Federation of Pharmaceutical Manufacturers & Associations (IFPMA) Biotech Working Group.[3]
Naming of monoclonal antibodies is governed by World Health Organization’s International Nonproprietary Name (INN):
- Human monoclonal antibody. INN names end in -umab. Example is olaratumab.
- Humanized monoclonal antibody. INN names end in -zumab. Example is benralizumab.
- Chimeric monoclonal antibody. INN names end in -ximab. Example is rituximab.
References
- ↑ Anonymous (2024), Antibody, monoclonal (English). Medical Subject Headings. U.S. National Library of Medicine.
- ↑ Anna-Maija Autere, Nicole Wagner and Georg-Burkhard Kresse from Roche on behalf of International Federation of Pharmaceutical Manufacturers & Associations (IFPMA) Biotech Working Group (2008), "International Nonproprietary Names for monoclonal antibodies: IFPMA proposal", WHO Drug Information 22 (2), pp. 97-107
- ↑ International Federation of Pharmaceutical Manufacturers & Associations (IFPMA) Biotech Working Group (2008), [http://www.ifpma.org/fileadmin/templates/ifpmaissues/pdfs/2008_03_21_IFPMA_Proposal_for_naming_of_new_monoclonals.pdf Proposal to the WHO INN Expert Group: Principles for naming of new monoclonal antibodies]